Tag: Biosimilars

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Russia registers its first domestically manufactured biosimilar of infliximab

The Russian Ministry of Health has registered BCD-055, the first Russian-made biosimilar of infliximab developed by BIOCAD, a biotech company. BIOCAD was developing the local biosimilar of infliximab since 2013.

Sandoz and Biocon partnered to develop multiple biosimilars

Sandoz, a Novartis division, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars

Russian biosimilar of adalimumab fully confirmed its equivalence

BIOСAD has successfully completed the main stage of clinical trials for the Russian biosimilar of adalimumab, a drug for the treatment of autoimmune and chronic inflammatory diseases

Samsung Bioepis received EU approval for its Herceptin biosimilar

Samsung Bioepis announced the European Commission’s marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab)

GEROPHARM is the first in Russia to conduct clamp studies of insulin biosimilars

GEROPHARM research center located in Strelna Special Economic Zone is engaged in a full cycle of advanced insulin drugs development

First Boehringer Ingelheim’s biosimilar drug is approved in Europe

Boehringer Ingelheim announced that the European Commission has granted marketing authorisation for Cyltezo a biosimilar to Humira

FDA approved first cancer biosimilar Mvasi

fda office
The U.S. Food and Drug Administration today approved Mvasi as a biosimilar to Avastin for the treatment of multiple types of cancer.

BIOСAD completes clinical trials of a biosimilar for anemia treatment

BIOСAD has completed the program of clinical trials for the first Russian-made darbepoetin alfa for the treatment of anemia in patients with chronic renal failure and oncological diseases

Authorities in India approved rituximab biosimilar produced by BIOCAD

The Central Drugs Standard Control Organization of India (CDSCO) approved for registration the first rituximab biosimilar fully manufactured by BIOCAD